Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ooking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes availabl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer ... protective stent system, today announced another positive study, reinforcing MGuard,s ... evaluation by Drs. Dmitry Dratva, Yaron Almagor, Jonathan Balkin, David ... Department of Cardiology at Shaare Zedek Medical ...
... SpeechTrans, a leader in app-based multi-language translation, ... Impaired. The new app enables the hearing impaired to ... Italian and German and Mandarin Chinese without the need ... With the new app, each person can simply speak ...
Cached Medicine Technology:Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 2Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 3Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 4Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 5Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 6SpeechTrans Offers Mobile Translation App for Hearing Impaired 2
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... initiate a range of care management programs for people living ... room (ER) use, improved health and lower costs. The ... (ACHP), are part of a report that is a comprehensive ... to improve care. Care management is the coordination ...
... Factors for,Developing MS, UB Study Shows, Summary: ... (CCSVI), which has attracted global attention as possibly being correlated ... the presence of risk factors in subjects who do not ... of 252 volunteers has found an association between CCSVI and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... fiddling with food and drink or doing some last-minute grooming, ... admit to being dangerously distracted while behind the wheel, a ... Interactive/HealthDay poll, most adults who drive on a regular ...
... or respirators put health care workers at risk of 2009 ... in the U.S., according to a study published in the ... the journal of the Society of Healthcare Epidemiology of America. ... Disease Control and Prevention (CDC), tracked 63 Southern California health ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women with lobular ... other forms of breast cancer to have a father who ... Swedish researchers examined the family history, pathology reports and hospital ... 2008. About 40 percent of the women had invasive ductal ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- About 40 percent ... before high school, which suggests that suicidal thoughts and behavior ... new study. As part of an ongoing survey, University ... or 19, about their history of suicide attempts. Nearly ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
... & Lomb PMMA Anterior Chamber Intraocular Lenses ... aphakia in patients 60 years of age ... been removed by primary intracapsular cataract extraction; ... is a structural reason that the anterior ...
... STAARVISC II is a sterile nonpyrogenic, transparent ... STAARVISC II contains 12 mg/ml of high ... sodium hyaluronate dissolved in physiological saline. In ... viscosity is 105,000 cps (105 Pa s) ...
... Methylcellulose solution that is especially well suited ... incision surgery. The low molecular weight of ... minimal risk of elevated intraocular pressure. The ... of the surgical field throughout capsulorhexis and ...
... AMO Vitrax features a low ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
Medicine Products: